Posts Tagged ‘Felipe García’

Categories

Posted in:

Tuesday February 02nd, 2016

IDIBAPS takes part in a 30 million euros project to develop new HIV vaccines

IDIBAPS takes part in the European HIV Vaccine Alliance (EHVA) to develop and evaluate new preventive and therapeutic vaccines. The European Commission grants with over 22 million euros in addition to the 6 million euros from Swiss Government. This effort is part of the European Commission Framework Programme for Research and Innovation (Horizon2020) and gathers together HIV leading scientists from 39 public institutions along with European, North American and African companies. Dr. Josep M. Gatell, head of the Infectious Diseases and AIDS IDIBAPS team, is the coordinator from this centre, and Drs. Felipe García, Montserrat Plana and Eloisa Yuste, researchers from the same group, also would join the project. The Spanish National Centre for Biotechnology of the CSIC (CNB-CSIC) also participates.

Read the rest of this entry »

Comments Closed
Friday June 12th, 2015

Hospital Clinic will coordinate the validation of an european ‘app’ to better monitor HIV patients

Researchers from the Hospital Clinic of Barcelona participate in the development and subsequent validation of an application for mobile devices that will facilitate monitoring of HIV patients and the doctor-patient communication. In the European project EmERGE, Hospital Clinic will validate the use of a mHealth platform in a study with 4,000 patients across Europe, 1.000 of whom will be participants of this center. The project, launched last May 6th and coordinated by the University of Sussex (UK), is part of Horizon 2020, the European Comission framework programme for research and innovation, it is endowed with a budget of 6 million euros and includes the participation of several European institutions.

Read the rest of this entry »

Comments Closed
Monday December 09th, 2013

EU Grants a Project to Test an Innovative HIV Vaccine Candidate in two phase I/IIa clinical trials

The four-year 6M€ European project iHIVARNA, funded by the European Commission, aims to successfully immunize antiretroviral-treated HIV-infected patients with 3 injections of the candidate universal HIV-TriMix-mRNA as an mRNA-based therapeutic vaccine with the final aim of improving the efficacy of therapeutic vaccination against HIV infection.

iHIVARNA is addressing the topic “Safety and efficacy of therapeutic vaccines” of the European Commission 7th Framework Programme Health 2013. The project brings together the expertise of a number of European groups (Spain, Belgium, and Netherlands) in dendritic cell targeting, rational design of immunogens, mRNA manufacturing and immuno-virological monitoring. This proposal continues the work in therapeutic vaccines performed in the last few years in the AIDS Research Unit of IDIBAPS leaded by Dr. Josep M Gatell and the Institute for AIDS Research IrsiCaixa. Dr. Felipe García, from IDIBAPS, is the coordinator of the iHIVARNA Consortium.

Read the rest of this entry »

Comments Closed
Monday December 02nd, 2013

A multimedia activity will help students to understand AIDS

IDIBAPS, in addition to working in disease prevention from a research perspective, is actively involved in activities oriented to society. Recently it published a multimedia activity to understand AIDS better, in collaboration with Ambientech and thanks to the Government of Catalonia’s ACDC 2012 funding for science dissemination. Through this interactive activity (in Spanish and Catalan) high school students, and anyone who wishes it, will learn why it is so difficult to combat the HIV virus, how can we prevent it and discuss about how we do approach its carriers.

Read the rest of this entry »

Comments Closed
Wednesday January 02nd, 2013

A therapeutic dendritic cell vaccine for HIV-1 infection controls virus replication temporarily

Combination antiretroviral therapy (cART) is a success of modern medicine that greatly improves survival and quality of life of HIV-1–infected patients. The major drawback is that cART must be maintained indefinitely causing inconveniences to patients, potential long term toxicities and carrying elevated economical cost. Research teams across the globe work to find an alternative to “cART for life”, such as inducing HIV-1–specific immune responses to control viral replication after discontinuation of cART. Investigators from the AIDS and Infectious Diseases team of the Hospital Clínic/IDIBAPS at University of Barcelona, led by Dr. Josep Maria Gatell, report today in Science Translational Medicine the safety, tolerability, immunogenicity and virologic response results obtained with a new therapeutic vaccine candidate.


Watch it on Youtube in English.

Read the rest of this entry »

Comments Closed
Tuesday September 25th, 2012

HIVACAT has been licensed by the CSIC to develop a vaccine against HIV

hivacat

The HIVACAT program for the development of this vaccine today announced the obtention of a license to advance in the development of a possible vaccine against HIV —the virus that causes AIDS. The license includes a vaccine candidate called “MVA-B”, developed by researcher Mariano Esteban from the Spanish National Research Council (CSIC).

The agreement has been formalized by ESTEVE and the IrsiCaixa Institute for AIDS Research on behalf of HIVACAT. Research, however, will also be conducted at the Hospital Clínic de Barcelona —also part of the HIVACAT consortium.

The obtention of this license coincides with the first anniversary of the presentation in Madrid of very promising results on its efficacy as a preventive vaccine. These results were obtained in a study conducted jointly by the Hospital Clínic of Barcelona and the Gregorio Marañón Hospital of Madrid.

Read the rest of this entry »

Comments Closed
Page 1 of 212